Yazar "Tumbay E." seçeneğine göre listele

Listeleniyor 1 - 8 / 8
  • Küçük Resim Yok
    Öğe
  • Küçük Resim Yok
    Öğe
    The clinical and mycological efficacy of single-dose (600 mg) isoconazole nitrate in vaginal mycosis [TEK DOZ 600 MG IZOKONAZOL NITRAT'IN VAGINAL MIKOZDA KLINIK VE MIKOLOJIK ETKINLIGI]
    (1995) Tunger A.; Tumbay E.; Capanoglu R.; Onvural A.
    OBJECTIVE: To investigate the efficacy of single-dose isoconazole nitrate (600 mg) in Candida vulvovaginitis. STUDY DESIGN: Single-dose topical isoconazole nitrate (600 mg) was topically given to 28 adult females (15 pregnant and 13 non-pregnant), proven to have Candidal vaginitis clinically and mycologically. The patients were both clinically and mycologically controlled one week (early control) and one month (late control) after therapy. RESULTS: In early and late controls clinical cure was 100 % and 100 %, mycological eradication 96 % and 82 %, respectively. Subjective complaints fell down under 20 % in late controls. There were no side-effects due to the drug. CONCLUSION: Single-dose isoconazole nitrate application has been found to be both clinically and mycologically efficient in the treatment of Candidal vaginitis in pregnant and non-pregnant women.
  • Küçük Resim Yok
    Öğe
    Effect of fluconazole prophylaxis on fungal colonisation in ICU patients
    (1994) Moral A.R.; Tumbay E.; Ulusoy B.; Aksoy N.; Cevik A.; Inci R.
    In this study, the effect of fluconazole prophylaxis on the incidence of fungal (yeast) colonization in multidisciplinary ICU patients were investigated. A total of 252 patients were mycologically screened in the first week of their hospitalization and followingly once every week. The specimens studied were blood (from venous route and from central venous catheter) urine catheter, endotracheal tubes, oral cavity, nares, skin and rectal swabs. The fungus isolated was candida. 91 received fluconazole 100 mg/day IV or enterally for prophylaxis and 161 served as the control group. Total number of samples in study was 2852 and 1723 of these samples were from the control group, 27.5% being positive. 1129 samples were taken from the prophylaxis group while 18.8% were positive. In conclusion, prophylactic treatment with 100 mg/day fluconazole significantly decreases the incidence of fungal colonization in ICU patients (p<0.01).
  • Küçük Resim Yok
    Öğe
    The efficacy of systemic fluconazole treatment in fungal keratitis
    (1993) Kose S.; Pamukcu K.; Akkin C.; Yagci A.; Tumbay E.
    Nine patients with fungal keratitis were treated with systemic fluconazole, which is a second generation triazole compound and has been proven to be an effective antifungal agent in experimental studies. The lesions healed with peroral 200 mg fluconazole per day, in a period of minimum 3, maximum 6 weeks. Neither a complication or any side-effect resulted from this therapy. One eye was eviscerated because of deteriorating infection and panophthalmitis. This is a pilot study investigating the efficacy of systemic fluconazole treatment in fungal keratitis, and we concluded that it is an effective alternative of antifungal treatment.
  • Küçük Resim Yok
    Öğe
    Erratum: Editorial (FEMS Immunology and Medical Mircobiology (2003) 35 (171))
    (Elsevier, 2003) Tumbay E.
    [No abstract available]
  • Küçük Resim Yok
    Öğe
    Estimated burden of serious human fungal diseases in Turkey
    (Blackwell Publishing Ltd, 2019) Hilmioğlu-Polat S.; Seyedmousavi S.; Ilkit M.; Hedayati M.T.; Inci R.; Tumbay E.; Denning D.W.
    The current number of fungal infections occurring each year in Turkey is unknown. We estimated the burden of serious human fungal diseases based on the population at risk, existing epidemiological data from 1920 to 2017 and modelling previously described by the LIFE program (http://www.LIFE-worldwide.org). Among the population of Turkey (80.8 million in 2017), approximately 1 785 811 (2.21%) people are estimated to suffer from a serious fungal infection each year. The model used predicts high prevalences of allergic fungal rhinosinusitis episodes (312 994 cases) (392/100 000), of severe asthma with fungal sensitisation (42 989 cases) (53.20 cases/100 000 adults per year), of allergic bronchopulmonary aspergillosis (32 594 cases) (40.33/100 000), of fungal keratitis (26 671 cases) (33/100 000) and of chronic pulmonary aspergillosis (5890 cases) (7.29/100 000). The estimated annual incidence for invasive aspergillosis is lower (3911 cases) (4.84/100 000 annually). Among about 22.5 million women aged 15-50 years, recurrent vulvovaginal candidiasis is estimated to occur in 1 350 371 (3342/100 000) females. The burden of three superficial fungal infections was also estimated: tinea pedis (1.79 million), tinea capitis (43 900) and onychomycosis (1.73 million). Given that the modelling estimates reported in the current study might be substantially under- or overestimated, formal epidemiological and comprehensive surveillance studies are required to validate or modify these estimates. © 2018 Blackwell Verlag GmbH
  • Küçük Resim Yok
    Öğe
    FEMS Immunology and Medical Microbiology: Editorial
    (Elsevier, 2003) Tumbay E.
    [No abstract available]
  • Küçük Resim Yok
    Öğe
    Skin infection on both legs caused by Acremonium strictum (case report)
    (King Faisal Specialist Hospital and Research Centre, 2015) Hilmioglu S.; Metin D.Y.; Tasbakan M.; Pullukcu H.; Akalin T.; Tumbay E.
    Acremonium species are saprophytic molds widely distributed in nature, existing in soil and decaying vegetation. Penetrating wounds, intravascular catheters and immunosuppression are risk factors for invasive infections of Acremonium. The fungus can also cause cutaneous infections and mycetoma in the immunocompetent; such infections occur in extremities open to trauma. In this paper, a female patient with skin infection due to Acremonium strictum in both legs is described.